Moderna Investors Should Brace for More Whiplash Moderna investors are bracing for more market volatility as the company's mRNA technology continues to make waves in the cancer treatment space. The latest development comes after a recent presentation at the European Society for Medical Oncology (ESMO) conference, where a study showed that an mRNA vaccine reduced the risk of melanoma recurrence by over 40 percent. The study, which was presented at the conference, marks a significant milestone for Moderna's mRNA technology, which has been touted as a game-changer in the fight against cancer. The company's shares have been on a rollercoaster ride in recent months, with investors eagerly awaiting updates on the progress of its cancer vaccine pipeline. The ESMO presentation has sparked renewed optimism among investors, with some analysts predicting that the vaccine could be a major breakthrough in the treatment of melanoma. However, others are cautioning that the road to approval and commercialization will be long and challenging. As the market continues to react to the latest developments, Moderna investors would do well to prepare for more whiplash. The company's stock has been known to be volatile, and the latest news is likely to send it on another wild ride.